Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NQO1 | P15559 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11601454 | 0.89 | PLAU (0.37) | PLAULMNAKDM4EMAPTMAPK1 | |
| SCHEMBL7322185 | 0.78 | LMNA (0.44) | PLAULMNAKDM4E | |
| SCHEMBL31471091 | 0.78 | PLAU (0.32) | PLAU | |
| SCHEMBL68280 | 0.78 | LMNA (0.50) | PLAULMNAKDM4E | |
| SCHEMBL19810216 | 0.74 | HTT (0.33) | PLAUKDM4E | |
| SCHEMBL6038800 | 0.74 | LMNA (0.52) | PLAULMNAKDM4E | |
| SCHEMBL31291363 | 0.73 | — | — | |
| SCHEMBL31471034 | 0.73 | HEXA (0.32) | LMNATDP1 | |
| SCHEMBL21826747 | 0.73 | HEXA (0.32) | LMNATDP1 | |
| SCHEMBL31241357 | 0.73 | CCNA2 (0.35) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171450-A1 | NOVEL COELENTERAZINE DERIVATIVES | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2025-05-29 | — | — | US | disclosed |
| WO-2023162995-A1 | NOVEL COELENTERAZINE DERIVATIVES | 国立大学法人電気通信大学 | 2023-08-31 | — | — | WO | disclosed |
| EP-2940020-B1 | LUCIFERIN LUMINESCENT SUBSTRATE OF MARINE OSTRACOD CRUSTACEAN AND METHOD FOR PRODUCTION THEREOF | AIST (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-9663477-B1 | Synthesis and structure of 3,5-diamino-2,6-di-(tert-butyl-NNO-azoxy) pyrazine as a critical intermediate in the synthesis of a novel energetic compound | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2940020-A1 | LUCIFERIN LUMINESCENT SUBSTRATE OF MARINE OSTRACOD CRUSTACEAN AND METHOD FOR PRODUCTION THEREOF | National Institute of Advanced Industrial Science and Technology (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-1930332-B1 | LUMINESCENT VARGULA LUCIFERIN SUBSTRATE AND PROCESS FOR PRODUCING THE SAME | NAT INST OF ADVANCED IND SCIEN (JP) | 2015-06-03 | — | — | EP | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8343729-B2 | Luciferin luminescent substrate of marine ostracod crustacean and method for production thereof | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2013-01-01 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-7989621-B2 | Method for producing substituted imidazo[1,2-A]pyrazines of (s)-1-(3-(2-sec-butyl-6-(1h-indol-3-yl)-3-oxo-3,7-dihydroimadazo[1,2-a]pyrazin-8-yl)propyl)guanidine | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2011-08-02 | — | — | US | disclosed |
| EP-2274300-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| US-20090136974-A1 | Luciferin Luminescent Substrate of Marine Ostracod Crustacean and Method for Production Thereof | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE TECHNOLOGY (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1930332-A1 | LUMINESCENT VARGULA LUCIFERIN SUBSTRATE AND PROCESS FOR PRODUCING THE SAME | National Institute Of Advanced Industrial Science and Technology (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | UNIVERSITY CATHOLIQUE DE LOUVAIN (BE) | 2004-02-19 | — | — | US | disclosed |
| EP-1292580-A1 | PYRAZINE AND IMIDAZOPYRAZINE DERIVATIVES AS ANTIOXIDANTS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001087853-A1 | ARYL-SUBSTITUTED N,N-HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE IN THERAPEUTICS AND DIAGNOSTICS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2001-11-22 | — | — | WO | disclosed |
| US-3987044-A | SEPARATION OF 2,3-DIAMINO-DIHALOPYRAZINES FROM MIXTURES AS NOVEL ASSOCIATION PRODUCTS WITH CERTAIN KETONES | THE DOW CHEMICAL COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136974-A1 | Luciferin Luminescent Substrate of Marine Ostracod Crustacean and Method for Production Thereof | GLB1, DCXR, GALR1 | PLAU 2229/4885LMNA 1930/4885NQO1 464/4885 |
| US-20250171450-A1 | NOVEL COELENTERAZINE DERIVATIVES | CBR3, CYP4F3, MRPL21 | PLAU 4280/4885LMNA 4728/4885NQO1 337/4885 |
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | NOX5, NOX4, CD22 | PLAU 1827/4885LMNA 3273/4885NQO1 27/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | PLAU 2856/4885LMNA 2861/4885NQO1 606/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | PLAU 3855/4885LMNA 3165/4885NQO1 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.